Highbridge Capital Management Reports 7.8% Stake in Fortress Biotech, Inc. via Warrants

Highbridge Capital Management, LLC has filed a Schedule 13G/A reporting a new beneficial ownership position in Fortress Biotech, Inc. (FBIO). As of the event date on March 31, 2026, the reporting person holds 2,734,654 shares of common stock, representing a 7.8% ownership stake in the company. This position is primarily comprised of shares issuable upon the exercise of warrants held by various Highbridge Funds, specifically mentioning the Highbridge Tactical Credit Master Fund, L.P. as having the right to receive dividends or proceeds from more than 5% of the outstanding stock. The filing indicates that these securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Highbridge Capital Management acts as the investment adviser to the funds holding these instruments. The percentage calculation is based on approximately 32.2 million shares outstanding as reported in the issuer's most recent annual report.